Na Qin

2.4k citations
85 papers · 1.2k indexed · 1 hit paper · h-index 21
Topics
Lung Cancer Treatments and Mutations (27 papers)RNA modifications and cancer (20 papers)Cancer-related molecular mechanisms research (19 papers)
Journals
Journal of Clinical OncologySHILAP Revista de lepidopterologíaPLoS ONE
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Na Qin

76 papers receiving 1.2k citations

Hit Papers

The burden of Gastric Cancer and possible risk factors fr...20252026202551015

Peers

Na Qin
Comparison fields: 5 of 94
  • Molecular Biology 717
  • Cancer Research 534
  • Pulmonary and Respiratory Medicine 335
  • Oncology 292
  • Immunology 86
Replace Xin Yin with:
Xin Yin China
Hongping Yu China
Shiruyeh Schokrpur United States
Valeria Cancila Italy
Erbao Bian China
María Dirlei Begnami Brazil
Qingcheng Yang China
Meryem Gülfem Öner Germany
F Viguié France
Na Qin relative to Xin Yin China Xin Yin's profile →
Citations per field
00.5×9.2×
Xin Yin · 1×
Citations per year

Countries citing papers authored by Na Qin

Since Specialization
Citations

This map shows the geographic impact of Na Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Qin more than expected).

Fields of papers citing papers by Na Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Qin. The network helps show where Na Qin may publish in the future.

Co-authorship network of co-authors of Na Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Na Qin. A scholar is included among the top collaborators of Na Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Qin. Na Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 1
3 0
4 6
5 2
6 51
7 39
8 24
9 3
10 21
11 17
12 9
13 39
14 7
15 79
16 6
17 21
18 47
19 7
20 48

About Na Qin

Na Qin is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 85 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (27 papers), RNA modifications and cancer (20 papers) and Cancer-related molecular mechanisms research (19 papers). The work is most often cited by research in Cancer Research (534 citations), Oncology (292 citations) and Molecular Biology (717 citations). Na Qin has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Juncheng Dai, Hongxia Ma, Hongbing Shen, Zhibin Hu, Guangfu Jin, Xi Li, Jing Zhou, Cheng Wang, Wen Zhou and Meng Zhu. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026